首页>
外国专利>
Composition of sustained Release injection intramuscularly, comprising a Drug, a biocompatible based Copolymer of lactic acid and Glycolic Acid, with a Molecular weight between 30 and 46 kDa and an inherent viscosity between 0.25 and 0.31 g / dl, and DMSO as Solvent Kit; pharmacist; And Method for its preparation.
Composition of sustained Release injection intramuscularly, comprising a Drug, a biocompatible based Copolymer of lactic acid and Glycolic Acid, with a Molecular weight between 30 and 46 kDa and an inherent viscosity between 0.25 and 0.31 g / dl, and DMSO as Solvent Kit; pharmacist; And Method for its preparation.
展开▼
机译:肌内缓释注射剂的组合物,其包含药物,分子量为30至46 kDa,比浓对数粘度为0.25至0.31 g / dl的乳酸和乙醇酸的生物相容性共聚物,以及DMSO作为溶剂套件;药剂师;及其制备方法。
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention is directed to an injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and a DMSO solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 4 weeks and wherein the composition has a pharmacokinetic profile in vivo that makes it suitable to be administered each 4 weeks or even longer periods.
展开▼